Severity of Psoriasis and a few inflammatory markers.
Not Applicable
- Conditions
- Health Condition 1: L404- Guttate psoriasisHealth Condition 2: L408- Other psoriasisHealth Condition 3: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2022/09/045319
- Lead Sponsor
- VINOLYN DSOUZA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All the patients with clinical diagnosis of psoriasis
2. Patients above the age of 12 years willing to participate in the study.
3. Patients who were on systemic treatment and had stopped 60 days prior to the study.
4. All age and sex matched healthy volunteers willing to participate in the study.
Exclusion Criteria
1. Patients with Psoriasis –on systemic drugs like Methotrexate, Cyclosporine, Apremilast and Biologicals for the last 60 days.
2. Patients with a clinical diagnosis of palmoplantar and pustular psoriasis and acute febrile illness.
3. Patients with other pre-existing skin disorders.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This study will help to estimate the levels of an inflammatory cytokine (TNF a) and a chronic inflammatory marker (CRP) in psoriasis in an Indian population. This study will also determine whether these levels can be correlated with the disease severity.Timepoint: 18 months
- Secondary Outcome Measures
Name Time Method The results will suggest the possible role of the markers in the etiopathogenesis and management of the disease.Timepoint: 18 months